{"id":"NCT00314132","sponsor":"Sanofi","briefTitle":"Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.","officialTitle":"Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2006-11","completion":"2006-11","firstPosted":"2006-04-13","resultsPosted":"2012-12-05","lastUpdate":"2012-12-06"},"enrollment":2004,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Encephalitis","Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"ChimeriVax-JE, Japanese Encephalitis vaccine","otherNames":["ChimeriVax™"]},{"type":"BIOLOGICAL","name":"0.9% Saline","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"ChimeriVax™ JE 4 log10 PFU Vaccine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.","primaryOutcome":{"measure":"Number of Participants Reporting Treatment Related Adverse Events Post Vaccination With Either ChimeriVax™-JE or a Placebo","timeFrame":"Day 0 up to 30 days post-vaccination","effectByArm":[{"arm":"Placebo","deltaMin":90,"sd":null},{"arm":"ChimeriVax™-JE 4 log10 PFU Vaccine","deltaMin":365,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":22,"countries":["United States","Australia"]},"refs":{"pmids":["20934459"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":403},"commonTop":["Headache","Malaise","Fatigue","Myalgia","Injection Site Pain"]}}